Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 9/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.83 |
| ▸ | TNF | P01375 | 1/20 | 0.83 |
| ▸ | MMP2 | P08253 | 1/20 | 0.83 |
| ▸ | MMP3 | P08254 | 1/20 | 0.83 |
| ▸ | MMP9 | P14780 | 1/20 | 0.83 |
| ▸ | MMP8 | P22894 | 1/20 | 0.83 |
| ▸ | MMP13 | P45452 | 1/20 | 0.83 |
| ▸ | MMP14 | P50281 | 1/20 | 0.83 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.83 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138144 | 1.00 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL25833 | 1.00 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892626 | 0.93 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892629 | 0.93 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892700 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892954 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL136239 | 0.91 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL26484 | 0.91 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL136238 | 0.91 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL1817324 | 0.91 | MMP1 (0.83) | MMP1ADAM17ADAMTS4TNFMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1081137-A1 | Selective inhibitors of aggrecanase in osteoarthritis treatment | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11124499-B2 | Pharmaceutical composition derived from Tecoma plant and a method for treating cancer | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2021-09-21 | — | — | US | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3812387-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20040192750-A1 | Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-20040192746-A1 | Thiazole derivatives | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6642232-B2 | Antitumor agents | SUGEN, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20020123513-A1 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | PFIZER PRODUCTS INC. | 2002-09-05 | — | — | US | disclosed |
| US-6388092-B2 | ANTITUMOR AGENT | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| EP-1081137-A1 | Selective inhibitors of aggrecanase in osteoarthritis treatment | Pfizer Products Inc. (US) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070715-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MMP1 2298/4885ADAM17 3541/4885ADAMTS4 3437/4885 |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PKM, PDK2 | MMP1 4359/4885ADAM17 4409/4885ADAMTS4 2249/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885ADAM17 4388/4885ADAMTS4 4609/4885 |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MMP1 2298/4885ADAM17 3541/4885ADAMTS4 3437/4885 |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | MMP1 3204/4885ADAM17 4830/4885ADAMTS4 2727/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885ADAM17 4388/4885ADAMTS4 4609/4885 |
| US-20020123513-A1 | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | PYGL, PYGM, G6PC1 | MMP1 157/4885ADAM17 831/4885ADAMTS4 1353/4885 |
| US-20040192746-A1 | Thiazole derivatives | CDK1, CDKL1, CDK5 | MMP1 2097/4885ADAM17 4365/4885ADAMTS4 2761/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885ADAM17 4388/4885ADAMTS4 4609/4885 |
| US-20040192750-A1 | Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease | CDK1, CDK3, CDK5 | MMP1 1624/4885ADAM17 4671/4885ADAMTS4 2764/4885 |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | MMP1 4034/4885ADAM17 4365/4885ADAMTS4 4247/4885 |
| US-11124499-B2 | Pharmaceutical composition derived from Tecoma plant and a method for treating cancer | TEC, TMSB10, MALT1 | MMP1 3159/4885ADAM17 3609/4885ADAMTS4 2138/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | MMP1 4636/4885ADAM17 3480/4885ADAMTS4 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.